Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Expected to Achieve 11.7% CAGR by 2029: Growth Forecast Insights

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Size By 2025?
The market size of Poly ADP-ribose polymerase (PARP) inhibitors has seen a swift expansion in the previous years. It is anticipated to escalate from $8.39 billion in 2024 to $9.41 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 12.1%. Factors such as clinical research, regulatory authorizations, market rivalry, drug combinations, and patient advocacy were influential in the historic period's growth.

How Big Is the Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Size Expected to Grow by 2029?
The market size of the poly ADP-ribose polymerase (PARP) inhibitor is projected to experience a swift increase in the years to come, hitting the mark of $14.67 billion by 2029 with a compound annual growth rate (CAGR) of 11.7%. Contributing factors to this anticipated growth span across expanded applications, personalized healthcare, development of biomarkers, healthcare economics, and up and coming markets. Foreseen trends for this estimated period encompass precision healthcare, strides in immunotherapy, targeted therapies, the use of artificial intelligence in discovering drugs, and a patient-focused healthcare system.

View the full report here:
https://www.thebusinessresearchcompany.com/report/poly-adp-ribose-polymerase-parp-inhibitor-global-market-report

Which Key Market Drivers Powering Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Expansion and Growth?
The uptick in incidences of ovarian cancer is poised to stimulate the expansion of the poly ADP-ribose polymerase (PARP) inhibitor market. Ovarian cancer, which is a malignant tumor that forms in a woman's ovaries, is on the rise, driven by factors such as genetic susceptibility, an aging populace, environmental elements, and hormonal imbalances. The ovaries play a critical role in the female reproductive system, generating eggs and female hormones. Poly ADP-Ribose Polymerase (PARP) Inhibitors come into play in the treatment of ovarian cancer, targeting specific DNA repair mechanisms, particularly in patients with BRCA mutations, thereby leading to synthetic lethality and increased tumor cell death. For instance, the World Ovarian Cancer Coalition, a non-profit organization based in Canada, reported in February 2024 that the annual death toll from ovarian cancer among women was projected to reach 350,956, a nearly 70% increase from the 2022 figure. Hence, the escalating prevalence of ovarian cancer is fueling the progression of the poly ADP-ribose polymerase (PARP) inhibitor market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15637&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Poly ADP-Ribose Polymerase (PARP) Inhibitor Market?
Leading enterprises in the poly ADP-ribose polymerase (PARP) inhibitor market are creating generic PARP inhibitors to facilitate personalized treatment for cancer patients with particular genetic mutations. These generic PARP inhibitors are drugs designed to inhibit the function of the enzyme poly ADP-ribose polymerase (PARP). For example, Zydus Lifesciences Limited, a pharmaceutical firm based in India, introduced Olaparib, a PARP inhibitor in the IBYRA brand, in March 2024, with the aim of improving access to progressive cancer treatments. IBYRA specifically targets certain genetic mutations present in breast, ovarian, prostate, and pancreatic cancers, providing a specialized and effective treatment strategy. The drug is especially advantageous for patients with HRD-positive or BRACA mutations, assisting in postponing disease advancement.

What Are the Emerging Segments in the Poly ADP-Ribose Polymerase (PARP) Inhibitor Market?
The poly ADP-ribose polymerase (PARP) inhibitor market covered in this report is segmented -

1) By Drug Type: Talazoparib, Veliparib, Olaparib, Other Drug Types
2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels
3) By Application: Ovarian Cancer, Breast Cancer, Other Applications
4) By End Users: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:
1) By Talazoparib: Talazoparib For Breast Cancer, Talazoparib For Ovarian Cancer, Talazoparib For Prostate Cancer, Talazoparib For Other Cancers
2) By Veliparib: Veliparib For Breast Cancer, Veliparib For Ovarian Cancer, Veliparib For Non-Small Cell Lung Cancer (Nsclc), Veliparib For Other Cancers
3) By Olaparib: Olaparib For Breast Cancer (Her2-negative), Olaparib For Ovarian Cancer (Brca-mutated), Olaparib For Prostate Cancer (Brca-Mutated), Olaparib For Pancreatic Cancer (Brca-Mutated), Olaparib For Other Cancers
4) By Other Drug Types: Niraparib, Rucaparib, Pembrolizumab (Combination Therapy With Parp Inhibitors), Other Parp Inhibitors (Emerging Drugs In Clinical Trials)

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=15637&type=smp

Who Are the Global Leaders in the Poly ADP-Ribose Polymerase (PARP) Inhibitor Market?
Major companies operating in the Poly ADP-ribose polymerase (PARP) inhibitor market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc., Takeda Pharmaceutical Company Limited, Merck KGaA, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Ipsen Biopharmaceuticals Inc., Genentech Inc., BioMarin Pharmaceutical Inc., Seattle Genetics Inc., Medivation Inc., Myriad Genetics Inc., PharmaMar S.A., Clovis Oncology, Nektar Therapeutics, Loxo Oncology Inc., Tolero Pharmaceuticals Inc., Everest Pharmaceuticals, Verastem Inc

Which are the Top Profitable Regional Markets for the Poly ADP-Ribose Polymerase (PARP) Inhibitor Industry?
North America was the largest region in the poly ADP-ribose polymerase (PARP) inhibitor market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the Poly ADP-ribose polymerase (PARP) inhibitor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15637

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.